Bluejay Diagnostics announces $1.59M registered direct offering and warrant private placement

Bluejay Diagnostics, Inc.

Company entered definitive agreement for registered direct offering of 216,000 shares at $7.365/share, raising ~$1.59M gross.
Concurrent private placement of warrants to purchase 216,000 shares at $7.24/share, exercisable for 5 years.
Proceeds intended for FDA approval activities, clinical studies, R&D, and general working capital.
H.C. Wainwright & Co. acted as exclusive placement agent; closing expected August 28, 2023.
Warrants and underlying shares sold unregistered under Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.59 million (effective 2023-08-24).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $1.59 million
Effective: 2023-08-24

Exact text from the filing

On August 24, 2023, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 216,000 shares of the Company’s common stock

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-071272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.